Efficacy and safety of ultra-rapid lispro versus lispro in children and adolescents with type 1 diabetes: The PRONTO-Peds trial.
R Paul WadwaLori M LaffelDenise R FrancoMary Anne DellvaAlastair W KnightsRobyn K PollomPublished in: Diabetes, obesity & metabolism (2022)
In children and adolescents with T1D, URLi demonstrated good glycaemic control, and noninferiority to lispro in HbA1c change for mealtime and postmeal URLi. When dosed at the beginning of meals, URLi reduced 1-hour PPG and PPG excursions versus lispro.